Symbols / GNTA $0.71 +3.46% Genenta Science S.p.A.
GNTA Chart
About
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Fundamentals
Scroll to Statements| Market Cap | 16.84M | Enterprise Value | -3.70M | Income | -6.53M | Sales | — | Book/sh | 1.10 | Cash/sh | 1.19 |
| Dividend Yield | — | Payout | 0.00% | Employees | 9 | IPO | — | P/E | — | Forward P/E | -1.10 |
| PEG | — | P/S | — | P/B | 0.65 | P/C | — | EV/EBITDA | 0.56 | EV/Sales | — |
| Quick Ratio | 13.90 | Current Ratio | 14.15 | Debt/Eq | 34.81 | LT Debt/Eq | — | EPS (ttm) | -0.39 | EPS next Y | -0.65 |
| EPS Growth | — | Revenue Growth | — | Earnings | — | ROA | -17.67% | ROE | -38.03% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 23.59M | Shs Float | 17.92M | Short Float | 0.63% |
| Short Ratio | 1.22 | Short Interest | — | 52W High | 10.00 | 52W Low | 0.59 | Beta | 0.71 | Avg Volume | 1.07M |
| Volume | 22.81K | Target Price | $6.97 | Recom | None | Prev Close | $0.69 | Price | $0.71 | Change | 3.46% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-10-02 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-05-13 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2023-02-08 | reit | HC Wainwright & Co. | — → Buy | $25 |
| 2023-01-05 | init | EF Hutton | — → Buy | $15 |
| 2022-07-25 | init | HC Wainwright & Co. | — → Buy | $25 |
| 2022-01-13 | init | Maxim Group | — → Buy | $21 |
- Is Genenta (GNTA) stock trading at a premium | - Community Momentum Stocks - Cổng thông tin điện tử Tỉnh Sơn La hu, 23 Apr 2026 02
- Is Genenta (GNTA) stock trading at a premium | - Expert Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai hu, 23 Apr 2026 02
- Genenta (GNTA) Stock: Summer Outlook (Institutional Selling) 2026-04-20 - Community Buy Signals - Xã Thanh Hà Mon, 20 Apr 2026 14
- Biotech-turned-defense group gets Nature Medicine GBM spotlight - Stock Titan Fri, 27 Feb 2026 08
- Genenta Science (GNTA): Assessing Valuation After Expanded Anemocyte Partnership Spurs Industry Optimism - Yahoo Finance Mon, 27 Oct 2025 07
- Genenta Science Secures $15 Million Through American Depositary Shares Offering | GNTA Stock News - Quiver Quantitative Mon, 27 Oct 2025 07
- Nasdaq warns Genenta Science (GNTA) on sub-$1 bid price and listing risk - Stock Titan ue, 14 Apr 2026 07
- Genenta (GNTA) Stock: Summer Outlook (Institutional Selling) 2026-04-20 - Viral Trade Signals - Cổng thông tin điện tử tỉnh Lào Cai Mon, 20 Apr 2026 14
- Genenta Science (GNTA) director awarded stock options on 20,000 ADS - Stock Titan Wed, 01 Apr 2026 07
- Genenta Science (GNTA) grants CFO 80,000 stock options at $0.63 - Stock Titan Wed, 01 Apr 2026 07
- Genenta Science (NASDAQ: GNTA) CMO granted stock options on 20,000 ADS - Stock Titan Wed, 01 Apr 2026 07
- Director at Genenta (NASDAQ: GNTA) receives 20,000 stock options grant - Stock Titan Wed, 01 Apr 2026 07
- Biotech firm Genenta pivots into tactical rifles and defense deals - Stock Titan ue, 27 Jan 2026 08
- Genenta (NASDAQ: GNTA) cancels vote on Saentra Forge rebrand - Stock Titan Mon, 23 Mar 2026 07
- Genenta (GNTA) director granted 20,000 options vesting from 2026 - Stock Titan Wed, 01 Apr 2026 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
6.60
-32.37%
|
9.76
-16.78%
|
11.73
+6.24%
|
11.04
|
| Research And Development |
|
2.70
-43.91%
|
4.81
-25.66%
|
6.47
+21.27%
|
5.34
|
| Selling General And Administration |
|
3.90
-21.15%
|
4.95
-5.84%
|
5.26
-7.83%
|
5.71
|
| General And Administrative Expense |
|
3.90
-21.15%
|
4.95
-5.84%
|
5.26
-7.83%
|
5.71
|
| Salaries And Wages |
|
1.98
-20.03%
|
2.48
-2.25%
|
2.54
-1.07%
|
2.56
|
| Other Gand A |
|
1.90
-22.54%
|
2.45
-9.12%
|
2.70
+43.25%
|
1.89
|
| Other Operating Expenses |
|
—
|
—
|
—
|
—
|
| Total Expenses |
|
6.60
-32.37%
|
9.76
-16.78%
|
11.73
+6.24%
|
11.04
|
| Operating Income |
|
-6.60
+32.37%
|
-9.76
+16.78%
|
-11.73
-6.24%
|
-11.04
|
| Total Operating Income As Reported |
|
-6.60
+32.37%
|
-9.76
+16.78%
|
-11.73
-6.24%
|
-11.04
|
| EBITDA |
|
-6.58
+32.35%
|
-9.72
+16.86%
|
-11.69
-5.91%
|
-11.04
|
| Normalized EBITDA |
|
-6.03
+39.47%
|
-9.96
+13.19%
|
-11.47
+13.89%
|
-13.32
|
| Reconciled Depreciation |
|
0.03
-36.93%
|
0.04
+4.88%
|
0.04
+591.42%
|
0.01
|
| EBIT |
|
-6.60
+32.37%
|
-9.76
+16.78%
|
-11.73
-6.24%
|
-11.04
|
| Total Unusual Items |
|
-0.55
-326.58%
|
0.24
+211.11%
|
-0.22
-109.48%
|
2.29
|
| Total Unusual Items Excluding Goodwill |
|
-0.55
-326.58%
|
0.24
+211.11%
|
-0.22
-109.48%
|
2.29
|
| Net Income |
|
-6.53
+26.73%
|
-8.91
+23.47%
|
-11.65
-37.36%
|
-8.48
|
| Pretax Income |
|
-6.53
+26.73%
|
-8.91
+23.47%
|
-11.65
-37.36%
|
-8.48
|
| Net Non Operating Interest Income Expense |
|
0.61
+649.95%
|
0.08
-73.76%
|
0.31
+736.16%
|
0.04
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
—
|
| Net Interest Income |
|
0.61
+649.95%
|
0.08
-73.76%
|
0.31
+736.16%
|
0.04
|
| Interest Expense |
|
—
|
—
|
—
|
—
|
| Interest Income Non Operating |
|
0.61
+649.95%
|
0.08
-73.76%
|
0.31
+736.16%
|
0.04
|
| Interest Income |
|
0.61
+649.95%
|
0.08
-73.76%
|
0.31
+736.16%
|
0.04
|
| Other Income Expense |
|
-0.53
-169.37%
|
0.77
+447.52%
|
-0.22
-108.77%
|
2.53
|
| Other Non Operating Income Expenses |
|
0.01
-97.84%
|
0.53
+10965.29%
|
-0.00
-102.01%
|
0.24
|
| Gain On Sale Of Security |
|
-0.55
-326.58%
|
0.24
+211.11%
|
-0.22
-109.48%
|
2.29
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-6.53
+26.73%
|
-8.91
+23.47%
|
-11.65
-37.36%
|
-8.48
|
| Net Income From Continuing Operation Net Minority Interest |
|
-6.53
+26.73%
|
-8.91
+23.47%
|
-11.65
-37.36%
|
-8.48
|
| Net Income From Continuing And Discontinued Operation |
|
-6.53
+26.73%
|
-8.91
+23.47%
|
-11.65
-37.36%
|
-8.48
|
| Net Income Continuous Operations |
|
-6.53
+26.73%
|
-8.91
+23.47%
|
-11.65
-37.36%
|
-8.48
|
| Normalized Income |
|
-5.98
+34.63%
|
-9.15
+19.91%
|
-11.43
-6.17%
|
-10.76
|
| Net Income Common Stockholders |
|
-6.53
+26.73%
|
-8.91
+23.47%
|
-11.65
-37.36%
|
-8.48
|
| Diluted EPS |
|
-0.33
+32.65%
|
-0.49
+23.44%
|
-0.64
-36.17%
|
-0.47
|
| Basic EPS |
|
-0.33
+32.65%
|
-0.49
+23.44%
|
-0.64
-36.17%
|
-0.47
|
| Basic Average Shares |
|
19.71
+7.86%
|
18.27
+0.31%
|
18.22
+0.00%
|
18.22
|
| Diluted Average Shares |
|
19.71
+7.86%
|
18.27
+0.31%
|
18.22
+0.00%
|
18.22
|
| Diluted NI Availto Com Stockholders |
|
-6.53
+26.73%
|
-8.91
+23.47%
|
-11.65
-37.36%
|
-8.48
|
| Insurance And Claims |
|
0.02
+14.73%
|
0.02
-17.20%
|
0.02
-98.26%
|
1.26
|
| Total Other Finance Cost |
|
—
|
—
|
-0.31
-736.16%
|
-0.04
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
31.89
+115.12%
|
14.82
-33.66%
|
22.35
-33.17%
|
33.44
|
| Current Assets |
|
29.98
+107.14%
|
14.47
-31.91%
|
21.26
-32.99%
|
31.72
|
| Cash Cash Equivalents And Short Term Investments |
|
28.15
+122.35%
|
12.66
-32.57%
|
18.78
-36.98%
|
29.79
|
| Cash And Cash Equivalents |
|
5.53
+20.65%
|
4.58
+24.12%
|
3.69
-87.61%
|
29.79
|
| Cash Financial |
|
5.53
+20.65%
|
4.58
+24.12%
|
3.69
-87.61%
|
29.79
|
| Other Short Term Investments |
|
22.62
+180.04%
|
8.08
-46.45%
|
15.08
|
0.00
|
| Receivables |
|
1.29
-11.24%
|
1.45
-27.71%
|
2.00
+28.24%
|
1.56
|
| Taxes Receivable |
|
1.29
-11.24%
|
1.45
-27.71%
|
2.00
+28.24%
|
1.56
|
| Prepaid Assets |
|
0.21
+34.62%
|
0.15
-62.65%
|
0.41
+184.93%
|
0.14
|
| Current Deferred Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
0.34
+60.05%
|
0.21
+226.04%
|
0.06
-70.53%
|
0.22
|
| Total Non Current Assets |
|
1.91
+444.07%
|
0.35
-67.82%
|
1.09
-36.45%
|
1.72
|
| Net PPE |
|
0.02
-47.66%
|
0.04
-48.27%
|
0.08
-25.67%
|
0.11
|
| Gross PPE |
|
0.15
+5.40%
|
0.14
+3.27%
|
0.14
+10.50%
|
0.12
|
| Accumulated Depreciation |
|
-0.13
-28.56%
|
-0.10
-82.76%
|
-0.05
-343.01%
|
-0.01
|
| Machinery Furniture Equipment |
|
0.09
+0.00%
|
0.09
+0.00%
|
0.09
-29.07%
|
0.12
|
| Other Properties |
|
0.06
+14.27%
|
0.05
+9.12%
|
0.05
|
—
|
| Non Current Accounts Receivable |
|
1.88
+548.90%
|
0.29
-63.61%
|
0.80
-48.97%
|
1.56
|
| Other Non Current Assets |
|
0.00
-74.88%
|
0.02
-91.48%
|
0.21
+396.28%
|
0.04
|
| Total Liabilities Net Minority Interest |
|
10.05
+331.59%
|
2.33
+21.59%
|
1.91
-16.73%
|
2.30
|
| Current Liabilities |
|
2.12
+0.88%
|
2.10
+20.96%
|
1.74
-20.51%
|
2.18
|
| Payables And Accrued Expenses |
|
2.00
+13.47%
|
1.76
+18.98%
|
1.48
-21.48%
|
1.89
|
| Payables |
|
1.81
+263.41%
|
0.50
+6.89%
|
0.47
-60.98%
|
1.19
|
| Accounts Payable |
|
1.51
+374.87%
|
0.32
+7.75%
|
0.29
-71.69%
|
1.04
|
| Current Accrued Expenses |
|
0.19
-85.02%
|
1.26
+24.53%
|
1.01
+46.72%
|
0.69
|
| Employee Benefits |
|
0.33
+43.91%
|
0.23
+38.33%
|
0.16
+85.08%
|
0.09
|
| Other Current Liabilities |
|
0.12
-64.77%
|
0.34
+32.42%
|
0.26
-14.37%
|
0.30
|
| Total Non Current Liabilities Net Minority Interest |
|
7.93
+3364.36%
|
0.23
+27.71%
|
0.18
+54.28%
|
0.12
|
| Long Term Debt And Capital Lease Obligation |
|
7.60
|
—
|
—
|
—
|
| Long Term Debt |
|
7.60
|
—
|
—
|
—
|
| Non Current Pension And Other Postretirement Benefit Plans |
|
0.33
+43.91%
|
0.23
+38.33%
|
0.16
+85.08%
|
0.09
|
| Other Non Current Liabilities |
|
—
|
0.00
-92.07%
|
0.01
-46.38%
|
0.03
|
| Stockholders Equity |
|
21.84
+74.79%
|
12.50
-38.84%
|
20.43
-34.38%
|
31.14
|
| Common Stock Equity |
|
21.84
+74.79%
|
12.50
-38.84%
|
20.43
-34.38%
|
31.14
|
| Capital Stock |
|
84.26
+23.07%
|
68.46
+1.66%
|
67.34
+1.11%
|
66.60
|
| Common Stock |
|
84.26
+23.07%
|
68.46
+1.66%
|
67.34
+1.11%
|
66.60
|
| Share Issued |
|
23.43
+28.12%
|
18.29
+0.40%
|
18.22
+0.00%
|
18.22
|
| Ordinary Shares Number |
|
23.43
+28.12%
|
18.29
+0.40%
|
18.22
+0.00%
|
18.22
|
| Additional Paid In Capital |
|
—
|
—
|
0.00
|
0.00
|
| Retained Earnings |
|
-62.59
-11.65%
|
-56.06
-18.91%
|
-47.14
-32.93%
|
-35.47
|
| Gains Losses Not Affecting Retained Earnings |
|
0.17
+87.20%
|
0.09
-61.52%
|
0.23
|
0.00
|
| Other Equity Adjustments |
|
0.17
+87.20%
|
0.09
-61.52%
|
0.23
|
—
|
| Total Equity Gross Minority Interest |
|
21.84
+74.79%
|
12.50
-38.84%
|
20.43
-34.38%
|
31.14
|
| Total Capitalization |
|
29.44
+135.63%
|
12.50
-38.84%
|
20.43
-34.38%
|
31.14
|
| Working Capital |
|
27.86
+125.17%
|
12.37
-36.61%
|
19.52
-33.91%
|
29.54
|
| Invested Capital |
|
29.44
+135.63%
|
12.50
-38.84%
|
20.43
-34.38%
|
31.14
|
| Total Debt |
|
7.60
|
—
|
—
|
—
|
| Net Debt |
|
2.08
|
—
|
—
|
—
|
| Net Tangible Assets |
|
21.84
+74.79%
|
12.50
-38.84%
|
20.43
-34.38%
|
31.14
|
| Tangible Book Value |
|
21.84
+74.79%
|
12.50
-38.84%
|
20.43
-34.38%
|
31.14
|
| Dueto Related Parties Current |
|
0.30
+66.74%
|
0.18
+5.40%
|
0.17
+12.44%
|
0.15
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-6.87
-10.06%
|
-6.24
+44.31%
|
-11.21
-51.05%
|
-7.42
|
| Cash Flow From Continuing Operating Activities |
|
-6.87
-10.06%
|
-6.24
+44.31%
|
-11.21
-51.05%
|
-7.42
|
| Net Income From Continuing Operations |
|
-6.53
+26.73%
|
-8.91
+23.47%
|
-11.65
-37.36%
|
-8.48
|
| Depreciation Amortization Depletion |
|
0.03
-36.93%
|
0.04
+4.88%
|
0.04
+591.42%
|
0.01
|
| Depreciation |
|
0.03
-36.93%
|
0.04
+4.88%
|
0.04
+591.42%
|
0.01
|
| Depreciation And Amortization |
|
0.03
-36.93%
|
0.04
+4.88%
|
0.04
+591.42%
|
0.01
|
| Other Non Cash Items |
|
—
|
—
|
—
|
0.03
|
| Pension And Employee Benefit Expense |
|
0.10
+58.48%
|
0.06
-16.62%
|
0.08
+29.73%
|
0.06
|
| Stock Based Compensation |
|
1.01
+19.18%
|
0.85
+14.51%
|
0.74
+2.37%
|
0.72
|
| Operating Gains Losses |
|
0.10
+58.48%
|
0.06
-16.62%
|
0.08
-16.23%
|
0.09
|
| Unrealized Gain Loss On Investment Securities |
|
0.10
|
0.00
|
0.00
|
—
|
| Net Foreign Currency Exchange Gain Loss |
|
—
|
0.00
|
0.00
-100.00%
|
0.03
|
| Change In Working Capital |
|
-1.58
-191.94%
|
1.72
+511.27%
|
-0.42
-273.78%
|
0.24
|
| Change In Prepaid Assets |
|
-0.02
-102.57%
|
0.67
+220.45%
|
-0.55
-35.96%
|
-0.41
|
| Change In Payables And Accrued Expense |
|
0.24
-15.56%
|
0.28
+169.38%
|
-0.41
-147.58%
|
0.85
|
| Change In Accrued Expense |
|
-1.07
-531.58%
|
0.25
-22.96%
|
0.32
+311.38%
|
-0.15
|
| Change In Payable |
|
1.31
+3988.30%
|
0.03
+104.41%
|
-0.73
-172.52%
|
1.00
|
| Change In Account Payable |
|
1.31
+3988.30%
|
0.03
+104.41%
|
-0.73
-172.52%
|
1.00
|
| Change In Other Current Assets |
|
-1.58
-325.66%
|
0.70
+17.23%
|
0.60
+239.50%
|
-0.43
|
| Change In Other Current Liabilities |
|
-0.22
-417.50%
|
0.07
+224.95%
|
-0.06
-124.71%
|
0.22
|
| Investing Cash Flow |
|
-14.54
-311.30%
|
6.88
+146.22%
|
-14.89
-54915.39%
|
-0.03
|
| Cash Flow From Continuing Investing Activities |
|
-14.54
-311.30%
|
6.88
+146.22%
|
-14.89
-54915.39%
|
-0.03
|
| Net PPE Purchase And Sale |
|
-0.01
-70.66%
|
-0.00
+67.60%
|
-0.01
+49.05%
|
-0.03
|
| Purchase Of PPE |
|
-0.01
-70.66%
|
-0.00
+67.60%
|
-0.01
+49.05%
|
-0.03
|
| Capital Expenditure |
|
-0.01
-70.66%
|
-0.00
+67.60%
|
-0.01
+49.05%
|
-0.03
|
| Net Investment Purchase And Sale |
|
-14.54
-311.05%
|
6.89
+146.29%
|
-14.88
|
0.00
|
| Purchase Of Investment |
|
-33.17
-102.47%
|
-16.38
-10.09%
|
-14.88
|
0.00
|
| Sale Of Investment |
|
18.63
-19.94%
|
23.27
|
0.00
|
0.00
|
| Financing Cash Flow |
|
22.29
+8127.65%
|
0.27
+50914.12%
|
0.00
|
0.00
|
| Cash Flow From Continuing Financing Activities |
|
22.29
+8127.65%
|
0.27
+50914.12%
|
0.00
|
0.00
|
| Net Issuance Payments Of Debt |
|
7.50
|
0.00
|
0.00
|
—
|
| Issuance Of Debt |
|
7.50
|
0.00
|
0.00
|
—
|
| Long Term Debt Issuance |
|
7.50
|
0.00
|
0.00
|
—
|
| Net Long Term Debt Issuance |
|
7.50
|
0.00
|
0.00
|
—
|
| Net Common Stock Issuance |
|
—
|
—
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
—
|
—
|
0.00
|
0.00
|
| Net Other Financing Charges |
|
14.79
+5358.94%
|
0.27
+50914.12%
|
0.00
|
—
|
| Changes In Cash |
|
0.88
-4.18%
|
0.91
+103.50%
|
-26.10
-250.52%
|
-7.45
|
| Effect Of Exchange Rate Changes |
|
0.07
+400.09%
|
-0.02
-273.46%
|
-0.01
|
0.00
|
| Beginning Cash Position |
|
4.58
+24.12%
|
3.69
-87.61%
|
29.79
-19.99%
|
37.24
|
| End Cash Position |
|
5.53
+20.65%
|
4.58
+24.12%
|
3.69
-87.61%
|
29.79
|
| Free Cash Flow |
|
-6.88
-10.10%
|
-6.24
+44.34%
|
-11.22
-50.68%
|
-7.45
|
| Common Stock Issuance |
|
—
|
—
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
—
|
—
|
0.00
|
0.00
|
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|